1-Methyl-4-propan-2-ylpyrazolo[3,4-b]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 1-Methyl-4-propan-2-ylpyrazolo[3,4-b]pyridine
• 英文别名: 1-methyl-4-propan-2-ylpyrazolo[3,4-b]pyridine
• 化学式: C₁₀H₁₃N₃
• 分子量: 175.23
• InChiKey: FWSNXJBQHQJIHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] MONOACYLGLYCEROL LIPASE MODULATORS<br/>[FR] MODULATEURS DE LA MONOACYLGLYCÉROL LIPASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021191359A1

  公开（公告）日：2021-09-30

  Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: (I) wherein R1a, R1b, R2, and R3, are defined herein.

  化合物的融合和桥联化合物的化学式(I)，以及其药用可接受的盐、同位素、N-氧化物、溶剂合物和立体异构体，含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、紊乱和症状的方法，例如与疼痛、精神紊乱、神经紊乱（包括但不限于重度抑郁症、治疗抵抗性抑郁症、焦虑性抑郁症、自闭症谱系障碍、亚斯伯格综合症、双相情感障碍）、癌症和眼部疾病相关的方法：(I)其中R1a、R1b、R2和R3在此定义。
• SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS
  申请人：Portola Pharmaceuticals, Inc.

  公开号：US20140113931A1

  公开（公告）日：2014-04-24

  Provided are picolinamide compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

  提供了用于抑制Syk激酶的吡啶甲酰胺化合物，制备这种化合物所使用的中间体，制备这种化合物的方法，制备药物组成物的方法，抑制Syk激酶活性的方法以及治疗至少部分通过Syk激酶活性介导的疾病的方法。
• BICYCLIC OXA-LACTAM KINASE INHIBITORS
  申请人：PORTOLA PHARMACEUTICALS, INC.

  公开号：US20150252056A1

  公开（公告）日：2015-09-10

  Provided are bicyclic oxa-lactam compounds for inhibition of JAK/Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting JAK/Syk kinase activity, and methods for treating conditions mediated at least in part by JAK/Syk kinase activity.

  提供了双环氧内酰胺化合物，用于抑制JAK/Syk激酶，用于制备这种化合物的中间体，其制备方法，制备这种化合物的制药组合物，抑制JAK/Syk激酶活性的方法，以及治疗至少部分由JAK/Syk激酶活性介导的疾病的方法。
• BICYCLIC DIHYDROPYRIDONE KINASE INHIBITORS
  申请人：PORTOLA PHARMACEUTICALS, INC.

  公开号：US20150266871A1

  公开（公告）日：2015-09-24

  Provided are bicyclic dihydropyridone compounds for inhibiting of JAK/Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting JAK/Syk kinase activity, and methods for treating conditions mediated at least in part by JAK/Syk kinase activity.

  提供了用于抑制JAK/Syk激酶的双环二氢吡啶酮化合物，用于制备这种化合物的中间体，其制备方法，药物组合物，抑制JAK/Syk激酶活性的方法，以及治疗至少部分由JAK/Syk激酶活性介导的疾病的方法。
• Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists
  申请人：Nimbus Saturn, Inc.

  公开号：US11078201B2

  公开（公告）日：2021-08-03

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

  本发明提供了用于抑制 HPK1 和治疗 HPK1 介导的疾病的化合物、其组合物和使用方法。